EXHIBIT 99.1 Galapagos announces first quarter 2023 financial results Progress with immunology and oncology pipeline: First patients dosed in pivotal Phase 3 OLINGUITO study with filgotinib in axial spondyloarthritis (AxSpA) Clinical sites opened to start patient recruitment in Phase 2 GALARISSO study with TYK2 inhibitor product candidate, GLPG3667, in dermatomyositis (DM) On track to report topline results from two CAR-T Phase 1/2 studies in hemato-oncology mid-2023 Further expanding CAR-T point-of-care ne ...